Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...
Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...
Private health insurance premiums will be going up in 2026 — in some cases, by a lot. Congressional Democrats and Republicans ...
Some patients dropped out of the trial early because they had lost so much weight.
Crux, the first no-fee benefits platform working directly with pharmaceutical companies and employers of all sizes to expand transparent and affordable access to transformative FDA-approved ...
With a valid prescription, patients can access the starting dose of Zepbound single-dose vial (2.5 mg) for as low as $299 per ...
They’re definitely easier and more affordable than injectables, but do they work as well? Here’s what you need to know.
The Daily Overview on MSN
Eli Lilly cuts Zepbound weight-loss vial prices on its DTC site
Eli Lilly is cutting what self-paying patients shell out for its blockbuster obesity drug Zepbound when they buy single-dose ...
Citi Annual Global Healthcare Conference 2025 December 2, 2025 10:30 AM ESTCompany ParticipantsIlya Yuffa - Executive VP ...
13d
Eli Lilly cuts Zepbound price by up to 20%: How much the weight-loss drug costs now, where to buy
This is the second time Eli Lilly has cut prices of Zepbound on LillyDirect. The pharmaceutical company said it is making the ...
13d
Eli Lilly slashes Zepbound prices: Check out the updated costs and where to buy the weight-loss drug
Eli Lilly is cutting introductory Zepbound prices again, with the lowest dose now $299 monthly for cash-pay customers, a $50 ...
US pharma major Eli Lilly (NYSE: LLY) has lowered the price of Zepbound (tirzepatide) single-dose vials on its Lilly Direct ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback